<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03760588</url>
  </required_header>
  <id_info>
    <org_study_id>2017-004909-41</org_study_id>
    <nct_id>NCT03760588</nct_id>
  </id_info>
  <brief_title>Prevention of Cardiac Dysfunction During Breast Cancer Therapy</brief_title>
  <acronym>PRADAII</acronym>
  <official_title>PRevention of cArdiac Dysfunction During Adjuvant Breast Cancer Therapy: A Randomized, Placebo-controlled, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torbjorn Omland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KLINBEFORSK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Akershus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is the most common cancer among women. The modern post-surgery treatment with
      chemotherapy, immunotherapy, radiation and hormone therapy has improved the overall 5-years
      survival drastically. However, an unwanted effect of the post-surgery treatment is its
      potentially deleterious effect on the heart resulting in cardiac dysfunction. Angiotensin
      antagonists are used as part of the heart failure treatment. In smaller studies angiotensin
      antagonists have shown to have a cardioprotective effect during breast cancer treatment.
      LCZ696 is a potent drug that in addition to an angiotensin antagonist contains a neprilysin
      inhibitor. LCZ696 has proved to be superior to enalapril in chronic heart failure. In this
      randomized placebo controlled double blind trial we hypothesize that LCZ696 used
      concomitantly during anthracycline containing chemotherapy for breast cancer treatment
      prevents cardiac dysfunction as measured by cardiac magnetic resonance imaging (CMR). PRADA
      II is a Norwegian multicenter trial intending to recruit 300 patients and follow them for 18
      months with CMR, cardiac ultrasound, blood samples, functional capacity tests and health
      related quality of life questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo controlled, double blind design</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in left ventricular ejection fraction by cardiovascular magnetic resonance</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular ejection fraction by echocardiography</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular systolic global longitudinal strain by echocardiography</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular systolic global longitudinal strain by cardiovascular magnetic resonance (CMR)</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular end-systolic volume measured by CMR</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of a significant reduction in left ventricular systolic function measured by CMR or echocardiography</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
    <description>An absolute reduction in LVEF ≥ 5% by CMR or a relative percentage reduction of global longitudinal strain (GLS) &gt; 15%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cardiotoxicity measured by CMR or echocardiography</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
    <description>Absolute reduction in LVEF ≥ 10% to a value below 50% as measured either by CMR or Echocardiography, or incidence of clinical heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in circulating cardiac biomarkers</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
    <description>Cardiac biomarkers defined as cardiac troponins I and T measured by high sensitivity assays (hs-TnI and hs-TnT) and N-terminal proB-type natriuretic peptide (NT-proBNP)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events and serious adverse events</measure>
    <time_frame>From randomization to end of blinded therapy (18 months)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>LCZ696</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 (target dose 200 mg b.i.d.) and matching placebo will be provided orally in a 1:1 parallel fashion stratified by study site and for planned treatment with trastuzumab. Dose titration will be performed as follows: LCZ696 50 mg b.i.d. will be administered for 2-4 weeks and provided blood pressure &gt; 100 mmHg, no symptoms of hypotension or other side effects or adverse events (AE), followed by LCZ696 100 mg b.i.d. for 2 - 4 weeks. Provided blood pressure &gt; 100 mmHg, no symptoms of hypotension or other side effects or AE a further uptitration to LCZ696 200 mg b.i.d. will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched to the comparator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>Target dose 200 (97/103) mg b.i.d .</description>
    <arm_group_label>LCZ696</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Entresto®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with histological evidence of invasive early breast cancer scheduled for
             adjuvant therapy with anti-cancer regimens that include anthracyclines

          -  Eastern Cooperative Oncology Group performance status 0-1

          -  Sinus rhythm

        Exclusion criteria:

          -  Age &lt;18 years

          -  Renal failure, i.e. serum creatinine greater than 133 mol/L (1.5mg/dL) or estimated
             glomerular filtration rate (eGFR) &lt; 45 mL/min/1.73m2

          -  Hyperkalemia, i.e. serum potassium greater than 5.0 mmol/L

          -  Systolic blood pressure &lt; 100 mgHg

          -  Uncontrolled hypertension

          -  Acute myocardial infarction within the last three months

          -  Contraindication to ACEI or ARB or LCZ696, including previous hypersensitivity
             reaction, angioedema and renal artery stenosis

          -  ACEI, ARB, aldosterone antagonist or LCZ696 use within 4 weeks of study start

          -  Clear indication for ACEI, ARB, aldosterone antagonist or LCZ696 therapy, including
             symptomatic heart failure

          -  History of hemodynamically significant valvular disease

          -  Active liver disease, i.e. alanine aminotransferase or aspartate aminotransferase
             greater than 1.5 times the upper limit of normal

          -  Participation in another pharmaceutical clinical trial of an investigational medicinal
             product (IMP) less than 4 weeks prior to inclusion or use of other investigational
             drugs within 5 halflives of enrollment, whichever is longer

          -  Conditions that would affect the participants to comply with the study protocol as
             psychiatric or mental disorders, alcohol abuse or other substance abuse, suspected
             poor drug compliance, language barriers or other factors

          -  Contraindication or inability to undergo CMR examination

          -  Fertile women with inadequate birth control, pregnancy, and/or breastfeeding. Adequate
             contraception includes oral, injected or implanted hormonal methods of contraception,
             placement of an intrauterine device or system, vasectomized partner or sexual
             abstinence. Fertile women are defined as following menarche and until becoming
             postmenopausal unless permanently sterile. A postmenopausal state is defined as no
             menses for 12 months without an alternative medical cause

          -  Life expectancy &lt; 12 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torbjørn Omland, MD,PhD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Akershus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Torbjorn Omland, MD,PhD,MPH</last_name>
    <phone>004740107050</phone>
    <email>torbjorn.omland@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Geeta Gulati, MD,PhD</last_name>
    <phone>004799008982</phone>
    <email>geetagul@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Geisler, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alf Inge Larsen, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Norway</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Egil Blix, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torgeir Wethal, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2018</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Akershus</investigator_affiliation>
    <investigator_full_name>Torbjorn Omland</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>LCZ696</keyword>
  <keyword>CMR</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Cardio-oncology</keyword>
  <keyword>Circulating biomarkers</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Anthracyclines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

